Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2Na.H2O7P2 |
| Molecular Weight | 221.9387 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O
InChI
InChIKey=GYQBBRRVRKFJRG-UHFFFAOYSA-L
InChI=1S/2Na.H4O7P2/c;;1-8(2,3)7-9(4,5)6/h;;(H2,1,2,3)(H2,4,5,6)/q2*+1;/p-2
DescriptionSources: https://books.google.ru/books?id=cPjjBwAAQBAJ&printsec=frontcover&hl=ru#v=onepage&q&f=falseCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11401820 | https://www.ncbi.nlm.nih.gov/pubmed/27061894 | http://www.food-info.net/uk/e/e450.htm
Sources: https://books.google.ru/books?id=cPjjBwAAQBAJ&printsec=frontcover&hl=ru#v=onepage&q&f=false
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11401820 | https://www.ncbi.nlm.nih.gov/pubmed/27061894 | http://www.food-info.net/uk/e/e450.htm
Inorganic pyrophosphate (PPi ) has long been known as a by-product of many intracellular biosynthetic reactions. PPi plays the regulatory role in living systems, such as activities of enzymes, fidelity of syntheses of macromolecules, and proliferation of cells. PPi is used as a biochemical energy source instead of ATP especially in bacteria, protists, and plants. PPi may also regulate the formation and dissolution of bone as well as pathologic calcification of soft tissues and the formation of urinary stones. The formation of calcium pyrophosphate dihydrate crystals in the extracellular fluids of joints cause the disease called pseudogout. Sodium, potassium and calcium pyrophosphates (E450) are used as food additives as buffers and emulsifiers.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0030282 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | Stannous Pyrophosphate Approved Usehttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30046b6b-09ea-46b1-8e60-61c53e1e7282 |
|||
| Diagnostic | Stannous Pyrophosphate Approved Usehttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30046b6b-09ea-46b1-8e60-61c53e1e7282 |
|||
| Diagnostic | Stannous Pyrophosphate Approved Usehttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30046b6b-09ea-46b1-8e60-61c53e1e7282 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase. | 1980 Mar 28 |
|
| Antiviral effects of phosphonoformate (PFA, foscarnet sodium). | 1982 |
|
| PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase. | 1986 May |
|
| Nucleoside triphosphates promote the transformation of Ah receptor to its DNA-binding form. | 1991 Mar 1 |
|
| Identification of the amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in the pyrophosphate binding of antiviral nucleoside triphosphate analogs and phosphonoformate. Implications for multiple drug resistance. | 1993 Dec 14 |
|
| Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate. | 1998 Dec 15 |
|
| Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz. | 2005 Jan |
|
| Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. | 2008 Apr 10 |
|
| Hepatitis C virus helicase/NTPase: an efficient expression system and new inhibitors. | 2008 Jun |
Sample Use Guides
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
24451
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
267798
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
231-835-0
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
DTXSID7044261
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
H5WVD9LZUD
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
7758-16-9
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
m9980
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
C003319
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
H5WVD9LZUD
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
DISODIUM PYROPHOSPHATE
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
SUB190975
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
377
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY | |||
|
100000176207
Created by
admin on Fri Dec 15 15:36:45 GMT 2023 , Edited by admin on Fri Dec 15 15:36:45 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
